TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01137149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual- Psychotherapy
Description: The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
Study: NCT04063553

Intervention type: OTHER
Group type: OTHER
Intervention: Volunteers Service
Description: Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients.
Study: NCT03845517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 15 mg
Description: PF-06700841 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg
Description: PF-06700841 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 45 mg
Description: PF-06700841 45 mg
Study: NCT05560945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.32% Sodium Fluoride Dentifrice Toothpaste
Description: Toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Arginine Dentifrice
Description: Toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0% Arginine Dentifrice
Description: Toothpaste
Study: NCT00183599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Minutes of Simple Advice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Study: NCT04306445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GF-IGB: Obalon Balloon
Description: The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medically Supervised Meal Replacement Program: My New Weigh
Description: Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sleeve gastroplasty: (ESG)
Description: Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
Study: NCT04063553

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise brochure
Description: . The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
Study: NCT02151305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol, remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study: NCT02011685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home BP Telemonitoring (HBPTM)
Description: Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home BP Telemonitoring (HBPTM)
Description: Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Case Management (NCM)
Description: Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
Study: NCT01010412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (Sonosite Titan T-shaped ultrasound probe)
Description: Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Nerve Stimulation (Stimuplex (B Braun) needle)
Study: NCT00630825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00521820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
Study: NCT03182504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nacubactam
Description: Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem
Description: Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
Study: NCT02480569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR Measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR Measurement
Study: NCT01045382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cell injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic solution
Description: Isotonic solution injection
Study: NCT03794648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Interactive Supervised Therapy (MIST)
Description: MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
Study: NCT03745846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Composite Gel Containing Black Raspberry
Description: Composite Gel Containing Black Raspberry 3,000/preparation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Composite Gel Containing Black Raspberry-placebo
Study: NCT06213584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative rehabilitation
Description: Hotpack + TENS + streching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative rehabilitation
Description: Hotpack + TENS + streching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative rehabilitation
Description: Hotpack + TENS + streching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mullgan mobilization techniques
Description: Passive mobilization techniques during active movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pnf
Description: hold relax active movements
Study: NCT01168414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganfort
Description: Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duotrav
Description: Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
Study: NCT01174381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: Lifestyle modification for six months
Study: NCT04228679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium laser
Description: Erbium laser device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: Sham laser device
Study: NCT03211884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Thearpy
Description: The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet \& greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions.
Study: NCT00509951

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-session exposure treatment
Description: Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented one-session exposure treatment
Description: Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
Study: NCT02593097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo twice daily
Study: NCT01255345

Intervention type: OTHER
Intervention: Chronic pelvic pain
Description: A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
Study: NCT00887575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
Study: NCT01602211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive full access to INSPIRE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03227744

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: MAX-PC, GAD and FACT-P

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Surveys
Description: MAX-PC, GAD and FACT-P
Study: NCT03460444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT Oil Supplementation
Description: Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
Study: NCT04051645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathing through a system with adjustable flow resistance
Description: The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances.
Study: NCT02295293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhus Coriaria L. (Rhus)
Description: 500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule: 1 capsule twice daily for 6 weeks
Study: NCT00784277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone CR
Description: flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
Study: NCT03718208

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Paediatric Formula
Description: Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
Study: NCT00784277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone IR
Description: 10mg for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (CG5503)
Description: flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (CG5503)
Description: 50mg for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (CG5503)
Description: 75mg for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets and capsules 2 x a day for 28 days
Study: NCT02137603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients discharged home the same day following appendectomy
Description: Patients are discharged to home on the same day following appendectomy with oral antibiotics.
Study: NCT02041897

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-FNA
Description: Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.